Guide To The Turbulent Times At The Top of Teva
Executive Summary
While the rumor mill continues to turn over Pascal Soriot jumping ship from AstraZeneca to Teva, the experience of previous CEOs shows that the chair at the head of the Israeli drug maker’s table is a very hot seat indeed.
You may also be interested in...
Will Soriot Ditch AstraZeneca In Favor Of Teva… And A $20m Bonus?
Pascal Soriot is reportedly about to abandon his top role at UK big pharma AstraZeneca to join Israel's generics giant Teva – a switch that could see him receive a $20m signing bonus, if the rumors are to be believed.
Sanofi Prepares Pulmonologists As Dupixent Nears COPD Finishing Line
The French drugmaker has identified education as a key challenge ahead of its June action date for the huge-selling IL4/IL-13 inhibitor in the lung condition. An approval would make it the first biologic for the disease.
Pharma Firms Welcome 'Pragmatic' EU Reforms But Concerns Persist
The European parliament has voted for legislation it says will lead to fairer, more accessible healthcare. The continent's drugmakers are still not wholly convinced.